



Next-Gen Disease Screen Premium

Last Updated: Nov 20, 2023

Genome: Charles Warden

Confidence: All ☒ High Only

Results Summary

Explore Data

Guide

5.2K

Results Summary

This list represents a summary of the results of your disease screen.

? [What do these categories mean?](#)

☐ Genetic Risk

☐ Medication Related

☐ Possible Genetic Risk

☐ No Genetic Risk

☐ Possible Genetic Carrier

☐ Unknown Genetic Risk

0

8

Selected

4

Selected

38

Selected

5091

57

Condition Summary



Condition

Acenocoumarol Response – Dosage[View Description >](#) [View Symptoms >](#)**Alpha-1–Antitrypsin Deficiency**[View Description >](#) [View Symptoms >](#)**Atorvastatin Response – Metabolism/PK**[View Description >](#) [View Symptoms >](#)**Atorvastatin Response – Toxicity**[View Description >](#) [View Symptoms >](#)**Boceprevir, Peginterferon Alfa-2a, Peginterferon Alfa-2b and Ribavirin Response – Efficacy**[View Description >](#) [View Symptoms >](#)**Carbamazepine Response – Dosage**[View Description >](#) [View Symptoms >](#)**Cystic Fibrosis; CFTR-Related Disorders**[View Description >](#) [View Symptoms >](#)**Efavirenz Response – Metabolism/PK**[View Description >](#) [View Symptoms >](#)**Efavirenz Response – Toxicity**[View Description >](#) [View Symptoms >](#)

Etanercept Response – Efficacy[View Description >](#) [View Symptoms >](#)**Factor V Deficiency**[View Description >](#) [View Symptoms >](#)**Fluvastatin Response – Metabolism/PK**[View Description >](#) [View Symptoms >](#)**Fluvastatin Response – Toxicity**[View Description >](#) [View Symptoms >](#)**Hereditary Pancreatitis**[View Description >](#) [View Symptoms >](#)**Hereditary Spastic Paraplegia**[View Description >](#) [View Symptoms >](#)**Hereditary Spastic Paraplegia 7**[View Description >](#) [View Symptoms >](#)**Hereditary Spherocytosis Type 5**[View Description >](#) [View Symptoms >](#)**HMG CoA Reductase Inhibitors Response – Toxicity**[View Description >](#) [View Symptoms >](#)**Hormonal Contraceptives for Systemic Use Response – Toxicity**[View Description >](#) [View Symptoms >](#)**Inflammatory Bowel Disease 25**[View Description >](#) [View Symptoms >](#)**Interferons, Peginterferon Alfa–2a, Peginterferon Alfa–2b, and Ribavirin Response – Efficacy**[View Description >](#) [View Symptoms >](#)

Lovastatin Acid Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Lovastatin Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Lovastatin Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Methotrexate Response – Efficacy

[View Description >](#) [View Symptoms >](#)

Methotrexate Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Methotrexate Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Nevirapine Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Nicotine Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Peginterferon Alfa-2a Response – Efficacy

[View Description >](#)

Peginterferon Alfa-2a, Peginterferon Alfa-2b, and Ribavirin Response – Efficacy

[View Description >](#)

Peginterferon Alfa-2a, Peginterferon Alfa-2b, Ribavirin, and Telaprevir Response – Efficacy

[View Description >](#) [View Symptoms >](#)

Peginterferon Alfa-2b and Ribavirin Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Peginterferon Alfa-2b Response – Efficacy

[View Description >](#) [View Symptoms >](#)

Pitavastatin Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Platinum Compounds Response – Efficacy

[View Description >](#) [View Symptoms >](#)

Polycystic Kidney Disease, Adult Type

[View Description >](#) [View Symptoms >](#)

Pravastatin Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Renal Carnitine Transport Defect

[View Description >](#) [View Symptoms >](#)

Ribavirin Response – Efficacy

[View Description >](#) [View Symptoms >](#)

Rosuvastatin Response – Efficacy

[View Description >](#) [View Symptoms >](#)

Rosuvastatin Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Rosuvastatin Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Simvastatin Acid Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Simvastatin Response – Metabolism/PK

[View Description >](#) [View Symptoms >](#)

Simvastatin Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Sorafenib Response – Toxicity

[View Description >](#) [View Symptoms >](#)

Spondylocostal Dysostosis 2, Autosomal Recessive

[View Description >](#) [View Symptoms >](#)

Rows per page: 100 ▾ 1–50 of 50 < >

Data Summary

Showing 55 results for Yellow, Orange, and Teal Categories

☰ Select Columns ▾

Condition ↑↓	Your Status ↑↓
Sorafenib Response – Toxicity View Description > View Symptoms >	Risk (D)
Carbamazepine Response – Dosage View Description > View Symptoms >	Risk (D)

Etanercept Response – Efficacy View Description > View Symptoms >	Risk (D)
Hormonal Contraceptives for Systemic Use Response – Toxicity View Description > View Symptoms >	Possible Risk (CD)
Methotrexate Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (CD)
Rosuvastatin Response – Efficacy View Description > View Symptoms >	Possible Risk (CD)
Rosuvastatin Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (CD)
Nevirapine Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (CD)
Cystic Fibrosis; CFTR–Related Disorders View Description > View Symptoms >	Possible Risk (CD)
Efavirenz Response – Toxicity View Description > View Symptoms >	Possible Risk (CD)
Efavirenz Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (CD)

Peginterferon Alfa-2a, Peginterferon Alfa-2b, Ribavirin, and Telaprevir Response – Efficacy View Description > View Symptoms >	Possible Risk (CD)
Interferons, Peginterferon Alfa-2a, Peginterferon Alfa-2b, and Ribavirin Response – Efficacy View Description > View Symptoms >	Possible Risk (CD)
Boceprevir, Peginterferon Alfa-2a, Peginterferon Alfa-2b and Ribavirin Response – Efficacy View Description > View Symptoms >	Possible Risk (CD)
Peginterferon Alfa-2a, Peginterferon Alfa-2b, and Ribavirin Response – Efficacy View Description >	Possible Risk (CD)
Peginterferon Alfa-2a, Peginterferon Alfa-2b, Ribavirin, and Telaprevir Response – Efficacy View Description > View Symptoms >	Possible Risk (CD)
Peginterferon Alfa-2a Response – Efficacy View Description >	Possible Risk (CD)
Ribavirin Response – Efficacy View Description > View Symptoms >	Possible Risk (CD)

Warfarin Response – Dosage View Description > View Symptoms >	Possible Risk (CD)

Acenocoumarol Response – Dosage View Description > View Symptoms >	Possible Risk (CD)
Warfarin Response – Dosage View Description > View Symptoms >	Possible Risk (CD)
Nicotine Response – Toxicity View Description > View Symptoms >	Possible Risk (CD)
Warfarin Response – Dosage View Description > View Symptoms >	Possible Risk (CD)
Methotrexate Response – Toxicity View Description > View Symptoms >	Possible Risk (CD)
Factor V Deficiency View Description > View Symptoms >	Possible Risk (CD)
Methotrexate Response – Efficacy View Description > View Symptoms >	Carrier (C)
Platinum Compounds Response – Efficacy View Description > View Symptoms >	Carrier (C)
Peginterferon Alfa–2b and Ribavirin Response – Toxicity View Description > View Symptoms >	Carrier (C)

Hereditary Pancreatitis View Description > View Symptoms >	Possible Risk (LCLD)
Hereditary Spastic Paraplegia 7 View Description > View Symptoms >	Possible Risk (LCLD)
Hereditary Spastic Paraplegia View Description > View Symptoms >	Possible Risk (LCLD)
Simvastatin Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)
Pravastatin Response – Toxicity View Description > View Symptoms >	Possible Risk (PD)
Atorvastatin Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)
HMG CoA Reductase Inhibitors Response – Toxicity View Description > View Symptoms >	Possible Risk (PD)
Simvastatin Response – Toxicity View Description > View Symptoms >	Possible Risk (PD)
Rosuvastatin Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)

Simvastatin Acid Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)
Renal Carnitine Transport Defect View Description > View Symptoms >	Possible Risk (PD)
Rosuvastatin Response – Toxicity View Description > View Symptoms >	Possible Risk (PD)
Pitavastatin Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)
Lovastatin Response – Toxicity View Description > View Symptoms >	Possible Risk (PD)
Lovastatin Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)
Lovastatin Acid Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)
Fluvastatin Response – Toxicity View Description > View Symptoms >	Possible Risk (PD)
Fluvastatin Response – Metabolism/PK View Description > View Symptoms >	Possible Risk (PD)

Atorvastatin Response – Toxicity View Description > View Symptoms >	Possible Risk (PD)
Hereditary Pancreatitis View Description > View Symptoms >	Possible Risk (PCPD)
Polycystic Kidney Disease, Adult Type View Description > View Symptoms >	Possible Risk (PCPD)
Inflammatory Bowel Disease 25 View Description > View Symptoms >	Possible Risk (PCPD)
Alpha-1–Antitrypsin Deficiency View Description > View Symptoms >	Carrier (PC)
Rows 100 ▼ 1–55 of 55 < >	